SK Bioscience Co Ltd
KRX:302440
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
44 700
73 300
|
Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Balance Sheet
Balance Sheet Decomposition
SK Bioscience Co Ltd
Current Assets | 1.5T |
Cash & Short-Term Investments | 1.3T |
Receivables | 51.1B |
Other Current Assets | 118B |
Non-Current Assets | 544.7B |
Long-Term Investments | 22.4B |
PP&E | 415.7B |
Intangibles | 28.7B |
Other Non-Current Assets | 77.9B |
Current Liabilities | 128.5B |
Accounts Payable | 13B |
Accrued Liabilities | 10.9B |
Other Current Liabilities | 104.7B |
Non-Current Liabilities | 199.7B |
Long-Term Debt | 199B |
Other Non-Current Liabilities | 664.3m |
Balance Sheet
SK Bioscience Co Ltd
Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
---|---|---|---|---|---|---|---|
Assets | |||||||
Cash & Cash Equivalents |
4 489
|
14 380
|
24 972
|
98 028
|
225 287
|
127 026
|
|
Cash Equivalents |
4 489
|
14 380
|
24 972
|
98 028
|
225 287
|
127 026
|
|
Short-Term Investments |
99 189
|
80 088
|
183 736
|
1 547 635
|
1 250 218
|
1 141 816
|
|
Total Receivables |
43 472
|
32 429
|
54 008
|
48 135
|
89 661
|
22 342
|
|
Accounts Receivables |
42 873
|
32 241
|
31 476
|
39 027
|
41 059
|
18 235
|
|
Other Receivables |
599
|
188
|
22 532
|
9 107
|
48 602
|
4 108
|
|
Inventory |
31 876
|
36 378
|
70 275
|
135 046
|
187 406
|
80 649
|
|
Other Current Assets |
1 703
|
7 465
|
911
|
8 960
|
31 122
|
11 136
|
|
Total Current Assets |
180 729
|
170 741
|
333 902
|
1 837 804
|
1 783 694
|
1 382 969
|
|
PP&E Net |
172 831
|
190 770
|
189 479
|
220 983
|
293 057
|
315 923
|
|
Intangible Assets |
21 839
|
19 479
|
17 858
|
17 061
|
18 181
|
22 459
|
|
Note Receivable |
10 985
|
10 597
|
0
|
0
|
0
|
0
|
|
Long-Term Investments |
86
|
86
|
86
|
586
|
1 586
|
42 815
|
|
Other Long-Term Assets |
13 528
|
12 307
|
20 907
|
33 688
|
45 413
|
88 273
|
|
Total Assets |
399 997
N/A
|
403 980
+1%
|
562 232
+39%
|
2 110 123
+275%
|
2 141 931
+2%
|
1 852 439
-14%
|
|
Liabilities | |||||||
Accounts Payable |
11 077
|
18 372
|
17 505
|
63 812
|
11 053
|
3 370
|
|
Accrued Liabilities |
4 550
|
7 094
|
11 520
|
26 322
|
30 242
|
19 716
|
|
Short-Term Debt |
0
|
0
|
0
|
11 671
|
45 550
|
0
|
|
Current Portion of Long-Term Debt |
11 411
|
1 351
|
12 608
|
50 287
|
50 243
|
8 137
|
|
Other Current Liabilities |
23 572
|
18 692
|
139 006
|
307 860
|
242 949
|
104 397
|
|
Total Current Liabilities |
50 610
|
45 509
|
180 639
|
459 952
|
380 037
|
135 620
|
|
Long-Term Debt |
126 550
|
123 721
|
109 359
|
44 277
|
17 543
|
12 436
|
|
Other Liabilities |
3 592
|
2 015
|
8 443
|
4 581
|
2 649
|
528
|
|
Total Liabilities |
180 751
N/A
|
171 246
-5%
|
298 442
+74%
|
508 811
+70%
|
400 229
-21%
|
148 584
-63%
|
|
Equity | |||||||
Common Stock |
10 200
|
10 200
|
30 600
|
38 250
|
38 392
|
38 414
|
|
Retained Earnings |
9 043
|
22 308
|
53 236
|
405 305
|
533 378
|
549 421
|
|
Additional Paid In Capital |
201 245
|
201 545
|
181 419
|
1 157 064
|
1 160 008
|
1 160 456
|
|
Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
54 727
|
|
Other Equity |
1 242
|
1 319
|
1 465
|
693
|
9 924
|
10 292
|
|
Total Equity |
219 246
N/A
|
232 734
+6%
|
263 790
+13%
|
1 601 312
+507%
|
1 741 702
+9%
|
1 703 855
-2%
|
|
Total Liabilities & Equity |
399 997
N/A
|
403 980
+1%
|
562 232
+39%
|
2 110 123
+275%
|
2 141 931
+2%
|
1 852 439
-14%
|
|
Shares Outstanding | |||||||
Common Shares Outstanding |
61
|
61
|
61
|
77
|
77
|
77
|